- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Effect of iron chelating drug, Deferiprone and the water extract of green tea in the treatment of iron overload in local rabbits | ||
| Journal of University of Anbar for Pure Science | ||
| Article 6, Volume 12, Issue 2, 2018, Pages 23-32 PDF (541.44 K) | ||
| Document Type: Research Paper | ||
| DOI: 10.37652/juaps.2022.171777 | ||
| Authors | ||
| Zaid Mohammed Mubarak Al-Mahdawi* ; Ismail Khaleel Ibrahim | ||
| Tikreet University, College of Science, Biology Department | ||
| Abstract | ||
| The current study was designed to study and compare the effect of the iron chelating action of the green tea (Camellia sinensis) Aqueous extract of green tea at a concentration of 100 mg / 1 kg and compared with the oral medicine , Deferiprone used to remove iron from the body. 25 mg / kg body weight . and the study of some of the biochemical variables associated with iron overload. Ferrous sulphate, (tablets200mg) was used to raise the proportion of iron in laboratory animals. . The laboratory animals (rabbits weighing 1 .to 1.5 kg) were given 10 mg / kg body weight,The treated groups were divided into four groups (five rabbits per group). The groups included the control group without treatment with any substance. The second group was treated with iron only and the third group was treated with iron with green tea. The fourth group was treated with iron with DeferiproneThe treatment of the four groups lasted for one month and then the animals were starved. The blood sample was withdrawn from the rabbits according to the usual laboratory methods. The study included determination of hepcidin, total iron binding capacity, ferritin, and serum iron ,Laboratory results showed significant increase (P ≤ 0.01) in the concentrations of hepecidin for the second group compared with control group and significant decrease (P ≤ 0.01) for the third group and the fourth group compared with the control groupAs for the ferritin, there was a significant increase (P ≤ 0.01) for the second and third groups, while the fourth group did not differ significantly compared to the control groupAs for TIBC, there was a significant increase (P ≤ 0.01) for the fourth group compared to the control group. A significant decrease was observed for the second and third groups compared with the control group at (P ≤ 0.01)Serum iron was found to have a low significant differences (P ≤ 0.01) for the second, third and fourth groups when compared to the control group. | ||
| Keywords | ||
| الحدید; الشای الاخضر; عقار Deferiprone; الهیبسیدین; الأرانب | ||
| References | ||
|
Lutgens, F.K., and Tarbuck, E.J. (2000). Essentials of geology (Chapter 2), 7th edn (Upper Saddle River, NJ: Prentice Hall).
2. Drakesmith, H., and Prentice, A. (2008). Viral infection and iron metabolism. Nature Reviews Microbiology, vol 6(7) p: 541-552.
3. Hall, J. E. (2016). Guyton and Hall textbook of medical physiology. Elsevier Health Sciences.
4. McLean, E., Cogswell, M., Egli, I., Wojdyla, D., and De Benoist, B. (2009). Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993-2005. Public health nutrition, vol 12(4) p: 444.
5. Dunn, L. L., Rahmanto, Y. S.,and Richardson, D. R. (2007). Iron uptake and metabolism in the new millennium. Trends in cell biology, vol 17(2) p: 93-100.
6. Brittenham, G. M. (2000). Disorders of iron metabolism: iron deficiency and overload. Hematology: basic principles and practice, 3: 397-428.
7. Dweck, A. (1999). "Detoxifying materials fro botanicals "Botanical detoxification، vol 72(10)p:42-48.
8. Ang AL, Shah F, Davis B, et al. (2010) Deferiprone is associated with lower serum ferritin (SF) relative to liver iron concentration (LIC) than deferoxamine and deferasirox: implications for clinical practice [abstract]Blood (ASH Annual Meeting Abstracts) vol 116(21)p:4246.
9. Nakagawa, T., and Yokozawa, T. (2002). Direct scavenging of nitric oxide and superoxide by green tea. Food and Chemical Toxicology, vol 40(12), 1745-1750.
10.Al-Haddad, Asawer,G.H,(2014) Comparison of the effect of green tea beverage and letrozole drug in inhibition of aromatase in albino female rabbits, Msc thesis, College of Science, University of Tikrit.
11. Turnberg, L. A. (1965). Excessive oral iron therapy causing haemochromatosis. British medical journal vol, 1(5446)p: 1360.
12.Barton, J. C., Lee, P. L., West, C., & Bottomley, S. S. (2006). Iron overload and prolonged ingestion of iron supplements: Clinical features and mutation analysis of hemochromatosis‐associated genes in four cases. American Journal of Hematology, vol 81(10)P: 760-767.
13.Vaziri, N. D. (2014). Toxic effects of IV iron preparations in CKD patients. Nephrol News vol، 28(2) P: 4-5.
14. Zanninelli, G., Breuer, W., & Cabantchik, Z. I. (2009). Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients. British journal of haematology, vol 147(5) p: 744-751.
15. Girelli, D., Nemeth, E., and Swinkels, D. W. (2016). Hepcidin in the diagnosis of iron disorders. Blood,vol 127(23)p: 2809-2813.
16. Kemna, E. H., Kartikasari, A. E., van Tits, L. J., Pickkers, P., Tjalsma, H., and Swinkels, D. W. (2008). Regulation of hepcidin: insights from biochemical analyses on human serum samples. Blood Cells, Molecules, and Diseases, vol 40(3) p: 339-346.
17. Rochette, L., Gudjoncik, A., Guenancia, C., Zeller, M., Cottin, Y., and Vergely, C. (2014). The iron‐regulatory hormone hepcidin: A possible therapeutic target? Pharmacology & therapeutics.vol 146 :p 35-52.
18. Ganz, T., and Nemeth, E. (2012). Hepcidin and iron homeostasis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, vol 1823(9) p:1434-1443.
19. Dao, M.C., and Meydani, S.N. (2013). Iron biology, immunology, aging, and obesity: four fields connected by the small peptide hormone hepcidin. Advances in nutrition 4: 602‐617.
20. Product Information: Ferrous Sulfate 200mg tablets® Actavis, Barnstaple, EX32 8NS, UK. Available at: https://www.medicines.org.uk/emc/search- default_intl in November 2016
21.AL- Obedi, Widad M،(2012) Study of the effect of medicinal plant extracts on the concentration of melatonin and some physiological and histological variables in male white rats, Ph.D. Thesis, Faculty of Education, University of Tikrit.
22.Taher, A., Sheikh-Taha, M., Sharara, A., Inati, A., Koussa, S., Ellis, G.,and Hoffbrand, A. V. (2005). Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. Acta haematologica, vol 114(3)p: 146-149.
23. Pigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., and Loréal, O. (2001). A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. Journal of biological chemistry, vol 276(11)P: 7811-7819.
24. Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., and Ganz, T. (2003). Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood, vol 101(7) P:2461-2463.
25. AL-Saidi, Dahlia Nayeef.(2015). Study of Hepcidin Level and Transferrin Level in Samples of Iraqi Patients with Iron Overload and Iron Deficiency Disorders, M.Sc. Thesis, Al-Mustansiriyah University.
26. Lee, P. L., and Beutler, E. (2009). Regulation of hepcidin and iron-overload disease. Annual Review of Pathological Mechanical Disease, 4: 489-515.
27. Saewong, T., Ounjaijean, S., Mundee, Y., Pattanapanyasat, K., Fucharoen, S., Porter, J. B., and Srichairatanakool, S. (2010). Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice. Medicinal Chemistry, vol 6(2) p: 57-64.
28. Savulescu J، (2004). “Thalassaemia major: the murky story of deferiprone”. BMJ. vol 328 (7436) P: 358–359
29. Kalantar-Zadeh, K., Don, B. R., Rodriguez, R. A., and Humphreys, M. H. (2001). Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. American journal of kidney diseases, vol 37(3)p: 564-572
30. Kalender, B., Mutlu, B., Ersöz, M., Kalkan, A., and Yilmaz, A. (2002). The effects of acute phase proteins on serum albumin, transferrin and haemoglobin in haemodialysis patients. International journal of clinical practice, vol 56(7)p: 505-508.
31. Algren, D. A. (2010). Review of Oral Iron Chelators (Deferiprone and Deferasirox) for the Treatment of Iron Overload in Pediatric Patients. World Health Organization [on line], 1-22
32. Arosio P, Levi S. (2002)Ferritin, iron homeostasis, and oxidative damage. Free Radic Biol Med. vol 33: P :457-460
33. Kotze, M. J., Van Velden, D. P., Van Rensburg, S. J., and Erasmus, R. (2009). Pathogenic mechanisms underlying iron deficiency and iron overload: New insights for clinical application. EJIFCC, vol 20(2) p: 108.
34. Van der Weyden MB, Fong H, Hallam LJ, and Breidahl MJ. (1984)Basic ferritin content of red cells of patients with anemia and polycythemia vera. Pathology. vol 16(4) p:419–23
35. Rifai, N., and Ridker, P. M. (2003). Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation. Clinical Chemistry, vol 49(4)p: 666-669.
36. Magnus Halland,(2011), Journal OF MedicineToday _ july 2011, vol 12, P: 7
37. Kontoghiorghes, G. J., and Kolnagou, A. (2005). Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators. Current medicinal chemistry, vol 12(23)p: 2695-2709
38. Khudiar, K. K., and Naji, N. M. (2012). Studying the effective dose of polyphenols extracted from green tea in ameliorating the deleterious effect of iron overload in female rats. In Proceeding of the Eleventh Veterinary Scientific Conference Vol. 142, p: 152.
39. Kontoghiorghes, G. J., Pattichis, K., Neocleous, K., and Kolnagou, A. (2004). The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Current medicinal chemistry, vol 11(16)p: 2161-2183 | ||
|
Statistics Article View: 412 PDF Download: 338 |
||